Structure Therapeutics Inc.
GPCR- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001888886
No open-market purchases or sales by Structure Therapeutics Inc. insiders were filed in the last 90 days; 191 institutions reported holding it in 13F filings for Q2 2026, worth $3.62B in total; no superinvestor holds it.
Q3 2023 vs. Q2 2023
How the institutions holding Structure Therapeutics Inc. changed between Q2 2023 and Q3 2023.
All holders in Q3 2023All holders in Q2 2023
| Measure | Q2 2023 | Q3 2023 | Change |
|---|---|---|---|
| Holders | 48 | 84 | +36 |
| Shares | 17.6M | 32.8M | +15.1M (+85.8%) |
| Value | $699.4M | $1.64B | +$944.0M (+135.0%) |
New holders (42)
Institutions that held Structure Therapeutics Inc. at the end of Q3 2023 but not at the end of Q2 2023.
Sold out (6)
Institutions that held Structure Therapeutics Inc. at the end of Q2 2023 and filed for Q3 2023 without it.
| Institution | Shares, Q2 2023 | Value, Q2 2023 |
|---|---|---|
| Octagon Capital Advisors LP | 75,000 | $3.12M |
| Nantahala Capital Management, LLC | 50,000 | $2.08M |
| Renaissance Technologies LLC | 32,900 | $1.37M |
| Lynx1 Capital Management LP | 23,000 | $956.1K |
| Pinpoint Asset Management Ltd | 900 | $37.0K |
| UBS Group AG | 2 | $83 |